EPISODE · Aug 20, 2026 · 11 MIN
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
from NeuroFrontiers
No Label: Michael Irizarry, MD, MPH Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
Embed this episode
Ready to play
Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
0:00
11:37
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of NeuroFrontiers?
This episode is 11 minutes long.
When was this NeuroFrontiers episode published?
This episode was published on August 20, 2026.
Can I download this NeuroFrontiers episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!